Perspective on adeno-associated virus capsid modification for duchenne muscular dystrophy gene therapy

Human Gene Therapy

Volumn 26, Issue 12, 2015, Pages 786-800

  Nance, Michael E ^a   Duan, Dongsheng ^a  

^a University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; EPITOPE; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; CAPSID PROTEIN; DMD PROTEIN, HUMAN;

ARTICLE; CELLULAR IMMUNITY; CORRELATIONAL STUDY; DNA MODIFICATION; DNA SHUFFLING; DUCHENNE MUSCULAR DYSTROPHY; GENE INSERTION; GENETIC ENGINEERING; GENETIC RECOMBINATION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; MOSAICISM; NONHUMAN; POLYMERASE CHAIN REACTION; PROMOTER REGION; TISSUE SPECIFICITY; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS ENTRY; ANIMAL; CHEMISTRY; DEFICIENCY; DEPENDOPARVOVIRUS; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETICS; METABOLISM; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; PATHOLOGY; PROCEDURES; PROTEIN ENGINEERING; SKELETAL MUSCLE; SPECIES DIFFERENCE;

ANIMALS; CAPSID; CAPSID PROTEINS; DEPENDOVIRUS; DYSTROPHIN; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; PROTEIN ENGINEERING; SPECIES SPECIFICITY;

EID: 84951950340     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2015.107     Document Type: Article

References (172)

1. Kunkel LM. 2004 William Allan Award address. Cloning of the DMD gene. Am J Hum Genet 2005;76:205-214.
2. Kunkel LM, Monaco AP, Hoffman E, et al. Molecular studies of progressive muscular dystrophy (Duchenne). Enzyme 1987;38:72-75.
3. Rossiter BJ, Stirpe NS, Caskey CT. Report of the MDA gene therapy conference, Tucson, Arizona, September 27-28, 1991. Neurology 1992;42: 1413-1418.
4. Seto JT, Bengtsson NE, Chamberlain JS. Therapy of genetic disorders-novel therapies for Duchenne muscular dystrophy. Curr Pediatr Rep 2014;2:102-112.
5. Duan D. Duchenne muscular dystrophy gene therapy in the canine model. Hum Gene Ther Clin Dev 2015;26:57-69.
6. Carter BJ. Adeno-Associated virus and the development of adeno-Associated virus vectors: A historical perspective. Mol Ther 2004;10:981-989.
7. Flotte TR, Berns KI. Adeno-Associated virus: A ubiquitous commensal of mammals. Hum Gene Ther 2005;16:401-407.
8. Duan D, Sharma P, Yang J, et al. Circular intermediates of recombinant adeno-Associated virus have defined structural characteristics responsible for long term episomal persistence in muscle. J Virol 1998;72:8568-8577.
9. Schnepp BC, Jensen RL, Chen CL, et al. Characterization of adeno-Associated virus genomes isolated from human tissues. J Virol 2005;79: 14793-14803.
10. Le Hir M, Goyenvalle A, Peccate C, et al. AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy. Mol Ther 2013;21:1551-1558.
11. Dupont JB, Tournaire B, Georger C, et al. Shortlived recombinant adeno-Associated virus transgene expression in dystrophic muscle is associated with oxidative damage to transgene mRNA. Mol Ther Methods Clin Dev 2015;2: 15010.
12. Calcedo R, Wilson JM. Humoral immune response to AAV. Front Immunol 2013;4:341.
13. Agbandje-McKenna M, Kleinschmidt J. AAV capsid structure and cell interactions. Methods Mol Biol 2011;807:47-92.
14. Drouin LM, Agbandje-McKenna M. Adenoassociated virus structural biology as a tool in vector development. Future Virol 2013;8:1183-1199.
15. Miller EB, Gurda-Whitaker B, Govindasamy L, et al. Production, purification and preliminary X-ray crystallographic studies of adenoassociated virus serotype 1. Acta Crystallogr F Struct Biol Crystall Commun 2006;62:1271-1274.
16. Kronenberg S, Kleinschmidt JA, Bottcher B. Electron cryo-microscopy and image reconstruction of adeno-Associated virus type 2 empty capsids. EMBO Rep 2001;2:997-1002.
17. Xie Q, Bu W, Bhatia S, et al. The atomic structure of adeno-Associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci USA 2002;99:10405-10410.
18. Xie Q, Somasundaram T, Bhatia S, et al. Structure determination of adeno-Associated virus 2: Three complete virus particles per asymmetric unit. Acta Crystallogr D Biol Crystallogr 2003; 59:959-970.
19. Xie Q, Hare J, Turnigan J, et al. Large-scale production, purification and crystallization of wild-Type adeno-Associated virus-2. J Virol Methods 2004;122:17-27.
20. Zhang F, Aguilera J, Beaudet JM, et al. Characterization of interactions between heparin/ glycosaminoglycan and adeno-Associated virus. Biochemistry 2013;52:6275-6285.
21. O Donnell J, Taylor KA, Chapman MS. Adenoassociated virus-2 and its primary cellular receptor-Cryo-EM structure of a heparin complex. Virology 2009;385:434-443.
22. McCraw DM, O Donnell JK, Taylor KA, et al. Structure of adeno-Associated virus-2 in complex with neutralizing monoclonal antibody A20. Virology 2012;431:40-49.
23. Lerch TF, Xie Q, Ongley HM, et al. Twinned crystals of adeno-Associated virus serotype 3b prove suitable for structural studies. Acta Crystallogr F Struct Biol Crystall Commun 2009;65: 177-183.
24. Lerch TF, Xie Q, Chapman MS. The structure of adeno-Associated virus serotype 3B (AAV-3B): Insights into receptor binding and immune evasion. Virology 2010;403:26-36.
25. Kaludov N, Padron E, Govindasamy L, et al. Production, purification and preliminary X-ray crystallographic studies of adeno-Associated virus serotype 4. Virology 2003;306:1-6.
26. Govindasamy L, Padron E, McKenna R, et al. Structurally mapping the diverse phenotype of adeno-Associated virus serotype 4. J Virol 2006;80:11556-11570.
27. Walters RW, Agbandje-McKenna M, Bowman VD, et al. Structure of adeno-Associated virus serotype 5. J Virol 2004;78:3361-3371.
28. Afione S, DiMattia MA, Halder S, et al. Identification and mutagenesis of the AAV5 sialic acid binding region. J Virol 2015;89:1660-1072.
29. Govindasamy L, DiMattia MA, Gurda BL, et al. Structural insights into adeno-Associated virus serotype 5. J Virol 2013;87:11187-11199.
30. DiMattia M, Govindasamy L, Levy HC, et al. Production, purification, crystallization and preliminary X-ray structural studies of adenoassociated virus serotype 5. Acta Crystallogr F Struct Biol Crystall Commun 2005;61:917-921.
31. Xie Q, Lerch TF, Meyer NL, et al. Structurefunction analysis of receptor-binding in adenoassociated virus serotype 6 (AAV-6). Virology 2011;420:10-19.
32. Xie Q, Ongley HM, Hare J, et al. Crystallization and preliminary X-ray structural studies of adeno-Associated virus serotype 6. Acta Crystallogr F Struct Biol Crystall Commun 2008;64: 1074-1078.
33. Quesada O, Gurda B, Govindasamy L, et al. Production, purification and preliminary X-ray crystallographic studies of adeno-Associated virus serotype 7. Acta Crystallogr F Struct Biol Crystall Commun 2007;63:1073-1076.
34. Lane MD, Nam HJ, Padron E, et al. Production, purification, crystallization and preliminary X-ray analysis of adeno-Associated virus serotype 8. Acta Crystallogr F Struct Biol Crystall Commun 2005;61:558-561.
35. Nam HJ, Lane MD, Padron E, et al. Structure of adeno-Associated virus serotype 8, a gene therapy vector. J Virol 2007;81:12260-12271.
36. Nam HJ, Gurda BL, McKenna R, et al. Structural studies of adeno-Associated virus serotype 8 capsid transitions associated with endosomal trafficking. J Virol 2011;85:11791-11799.
37. Gurda BL, Raupp C, Popa-Wagner R, et al. Mapping a neutralizing epitope onto the capsid of adeno-Associated virus serotype 8. J Virol 2012;86:7739-7751.
38. Raupp C, Naumer M, Muller OJ, et al. The threefold protrusions of adeno-Associated virus type 8 are involved in cell surface targeting as well as postattachment processing. J Virol 2012; 86:9396-9408.
39. Mitchell M, Nam HJ, Carter A, et al. Production, purification and preliminary X-ray crystallographic studies of adeno-Associated virus serotype 9. Acta Crystallogr F Struct Biol Crystall Commun 2009;65:715-718.
40. DiMattia MA, Nam HJ, Van Vliet K, et al. Structural insight into the unique properties of adeno-Associated virus serotype 9. J Virol 2012;86:6947-6958.
41. Bell CL, Gurda BL, Van Vliet K, et al. Identification of the galactose binding domain of the adeno-Associated virus serotype 9 capsid. J Virol 2012;86:7326-7333.
42. Mikals K, Nam HJ, Van Vliet K, et al. The structure of AAVrh32.33, a novel gene delivery vector. J Struct Biol 2014;186:308-317.
43. Lerch TF, O Donnell JK, Meyer NL, et al. Structure of AAV-DJ, a retargeted gene therapy vector: Cryo-Electron microscopy at 4.5 A resolution. Structure 2012;20:1310-1320.
44. Xie Q, Spilman M, Meyer NL, et al. Electron microscopy analysis of a disaccharide analog complex reveals receptor interactions of adenoassociated virus. J Struct Biol 2013;184:129-135.
45. Hakim CH, Yue Y, Shin JH, et al. Systemic gene transfer reveals distinctive muscle transduction profile of tyrosine mutant AAV-1,-6, and-9 in neonatal dogs. Mol Ther Methods Clin Dev 2014; 1:14002.
46. Yue Y, Pan X, Hakim CH, et al. Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-Associated virus. Hum Mol Genet 2015; 24:5880-5890.
47. Yang Q, Mamounas M, Yu G, et al. Development of novel cell surface CD34-Targeted recombinant adeno-Associated virus vectors for gene therapy. Hum Gene Ther 1998;9:1929-1937.
48. Hoque M, Ishizu K, Matsumoto A, et al. Nuclear transport of the major capsid protein is essential for adeno-Associated virus capsid formation. J Virol 1999;73:7912-7915.
49. Girod A, Wobus CE, Zadori Z, et al. The VP1 capsid protein of adeno-Associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol 2002;83:973-978.
50. Stahnke S, Lux K, Uhrig S, et al. Intrinsic phospholipase A2 activity of adeno-Associated virus is involved in endosomal escape of incoming particles. Virology 2011;409:77-83.
51. Venkatakrishnan B, Yarbrough J, Domsic J, et al. Structure and dynamics of adeno-Associated virus serotype 1 VP1-unique N-Terminal domain and its role in capsid trafficking. J Virol 2013;87:4974-4984.
52. Sonntag F, Bleker S, Leuchs B, et al. Adenoassociated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J Virol 2006;80:11040-11054.
53. Rabinowitz JE, Xiao W, Samulski RJ. Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology 1999;265:274-285.
54. Wu P, Xiao W, Conlon T, et al. Mutational analysis of the adeno-Associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 2000;74:8635-8647.
55. Warrington KH, Jr., Gorbatyuk OS, Harrison JK, et al. Adeno-Associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol 2004;78:6595-6609.
56. Agbandje-McKenna M, Llamas-Saiz AL, Wang F, et al. Functional implications of the structure of the murine parvovirus, minute virus of mice. Structure 1998;6:1369-1381.
57. McKenna R, Olson NH, Chipman PR, et al. Threedimensional structure of Aleutian mink disease parvovirus: Implications for disease pathogenicity. J Virol 1999;73:6882-6891.
58. Agbandje M, Kajigaya S, McKenna R, et al. The structure of human parvovirus B19 at 8 A resolution. Virology 1994;203:106-115.
59. Tsao J, Chapman MS, Agbandje M, et al. The three-Dimensional structure of canine parvovirus and its functional implications. Science 1991;251: 1456-1464.
60. Girod A, Ried M, Wobus C, et al. Genetic capsid modifications allow efficient re-Targeting of adeno-Associated virus type 2. Nat Med 1999;5:1052-1056.
61. Grifman M, Trepel M, Speece P, et al. Incorporation of tumor-Targeting peptides into recombinant adeno-Associated virus capsids. Mol Ther 2001;3:964-975.
62. Shi W, Arnold GS, Bartlett JS. Insertional mutagenesis of the adeno-Associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther 2001;12:1697-1711.
63. Perabo L, Goldnau D, White K, et al. Heparan sulfate proteoglycan binding properties of adeno-Associated virus retargeting mutants and consequences for their in vivo tropism. J Virol 2006;80:7265-7269.
64. Perabo L, Buning H, Kofler DM, et al. In vitro selection of viral vectors with modified tropism: The adeno-Associated virus display. Mol Ther 2003;8:151-157.
65. Muller OJ, Kaul F, Weitzman MD, et al. Random peptide libraries displayed on adeno-Associated virus to select for targeted gene therapy vectors. Nat Biotechnol 2003;21:1040-1046.
66. Naumer M, Popa-Wagner R, Kleinschmidt JA. Impact of capsid modifications by selected peptide ligands on recombinant adeno-Associated virus serotype 2-mediated gene transduction. J Gen Virol 2012;93:2131-2141.
67. Ying Y, Muller OJ, Goehringer C, et al. Hearttargeted adeno-Associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther 2010;17:980-990.
68. Yu CY, Yuan Z, Cao Z, et al. A muscle-Targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery. Gene Ther 2009;16:953-962.
69. Michelfelder S, Kohlschutter J, Skorupa A, et al. Successful expansion but not complete restriction of tropism of adeno-Associated virus by in vivo biopanning of random virus display peptide libraries. PLoS One 2009;4:e5122.
70. Michelfelder S, Lee MK, deLima-Hahn E, et al. Vectors selected from adeno-Associated viral display peptide libraries for leukemia celltargeted cytotoxic gene therapy. Exp Hematol 2007;35:1766-1776.
71. White AF, Mazur M, Sorscher EJ, et al. Genetic modification of adeno-Associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells. Hum Gene Ther 2008;19:1407-1414.
72. White SJ, Nicklin SA, Buning H, et al. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-Associated virus vectors. Circulation 2004;109:513-519.
73. Opie SR, Warrington KH, Jr., Agbandje-McKenna M, Zolotukhin S, Muzyczka N. Identification of amino acid residues in the capsid proteins of adeno-Associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol 2003;77:6995-7006.
74. Varadi K, Michelfelder S, Korff T, et al. Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-Directed gene transfer vectors. Gene Ther 2012;19:800-809.
75. Michelfelder S, Varadi K, Raupp C, et al. Peptide ligands incorporated into the threefold spike capsid domain to re-Direct gene transduction of AAV8 and AAV9 in vivo. PLoS One 2011;6: e23101.
76. Feero WG, Li S, Rosenblatt JD, et al. Selection and use of ligands for receptor-mediated gene delivery to myogenic cells. Gene Ther 1997;4: 664-674.
77. Barry MA, Dower WJ, Johnston SA. Toward cell-Targeting gene therapy vectors: Selection of cell-binding peptides from random peptidepresenting phage libraries. Nat Med 1996;2: 299-305.
78. Samoylova TI, Smith BF. Elucidation of musclebinding peptides by phage display screening. Muscle Nerve 1999;22:460-466.
79. Flint PW, Li ZB, Lehar M, et al. Laryngeal muscle surface receptors identified using random phage library. Laryngoscope 2005;115:1930-1937.
80. Ghosh D, Barry MA. Selection of muscle-binding peptides from context-specific peptide-presenting phage libraries for adenoviral vector targeting. J Virol 2005;79:13667-13672.
81. McGuire MJ, Samli KN, Johnston SA, et al. In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo. J Mol Biol 2004;342:171-182.
82. Gao X, Zhao J, Han G, et al. Effective dystrophin restoration by a novel muscle-homing peptidemorpholino conjugate in dystrophin-Deficient mdx mice. Mol Ther 2014;22:1333-1341.
83. Waterkamp DA, Muller OJ, Ying Y, et al. Isolation of targeted AAV2 vectors from novel virus display libraries. J Gene Med 2006;8:1307-1319.
84. Yue Y, Li Z, Harper SQ, Davisson RL, et al. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 2003;108:1626-1632.
85. Mietzsch M, Broecker F, Reinhardt A, et al. Differential adeno-Associated virus serotypespecific interaction patterns with synthetic heparins and other glycans. J Virol 2014;88:2991-3003.
86. Kern A, Schmidt K, Leder C, et al. Identification of a heparin-binding motif on adeno-Associated virus type 2 capsids. J Virol 2003;77:11072-11081.
87. Levy HC, Bowman VD, Govindasamy L, et al. Heparin binding induces conformational changes in adeno-Associated virus serotype 2. J Struct Biol 2009;165:146-156.
88. Wu Z, Miller E, Agbandje-McKenna M, et al. Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-Associated virus types 1 and 6. J Virol 2006;80:9093-9103.
89. Walters RW, Yi SM, Keshavjee S, et al. Binding of adeno-Associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem 2001;21:21.
90. Handa A, Muramatsu S, Qiu J, et al. Adenoassociated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. J Gen Virol 2000;81:2077-2084.
91. Summerford C, Samulski RJ. Membraneassociated heparan sulfate proteoglycan is a receptor for adeno-Associated virus type 2 virions. J Virol 1998;72:1438-1445.
92. Kaludov N, Brown KE, Walters RW, et al. Adenoassociated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 2001;75: 6884-6893.
93. Shen S, Bryant KD, Brown SM, et al. Terminal N-linked galactose is the primary receptor for adeno-Associated virus 9. J Biol Chem 2011;286: 13532-13540.
94. Bell CL, Vandenberghe LH, Bell P, et al. The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J Clin Invest 2011;121:2427-2435.
95. Asokan A, Conway JC, Phillips JL, et al. Reengineering a receptor footprint of adenoassociated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol 2010; 28:79-82.
96. Adachi K, Enoki T, Kawano Y, et al. Drawing a high-resolution functional map of adenoassociated virus capsid by massively parallel sequencing. Nat Commun 2014;5:3075.
97. Shen S, Horowitz ED, Troupes AN, et al. Engraftment of a galactose receptor footprint onto adeno-Associated viral capsids improves transduction efficiency. J Biol Chem 2013;288:28814-28823.
98. Judd J, Ho ML, Tiwari A, et al. Tunable protease-Activatable virus nanonodes. ACS Nano 2014;8:4740-4746.
99. Louis Jeune V, Joergensen JA, Hajjar RJ, et al. Pre-Existing anti-Adeno-Associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods 2013;24:59-67.
100. Scallan CD, Jiang H, Liu T, et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 2006;107:1810-1817.
101. Rapti K, Louis-Jeune V, Kohlbrenner E, et al. Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther 2011;20:73-83.
102. Moskalenko M, Chen L, van Roey M, et al. Epitope mapping of human anti-Adeno-Associated virus type 2 neutralizing antibodies: Implications for gene therapy and virus structure. J Virol 2000;74:1761-1766.
103. Wobus CE, Hugle-Dorr B, Girod A, et al. Monoclonal antibodies against the adeno-Associated virus type 2 (AAV-2) capsid: Epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J Virol 2000;74:9281-9293.
104. Huttner NA, Girod A, Perabo L, et al. Genetic modifications of the adeno-Associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Ther 2003;10:2139-2147.
105. Tseng YS, Gurda BL, Chipman P, et al. Adenoassociated virus serotype 1 (AAV1)-And AAV5-Antibody complex structures reveal evolutionary commonalities in parvovirus antigenic reactivity. J Virol 2015;89:1794-1808.
106. Gurda BL, DiMattia MA, Miller EB, et al. Capsid antibodies to different adeno-Associated virus serotypes bind common regions. J Virol 2013; 87:9111-9124.
107. Englund P, Lindroos E, Nennesmo I, et al. Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am J Pathol 2001;159:1263-1273.
108. Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity in Duchenne s muscular dystrophy. N Engl J Med 2010;363:1429-1437.
109. Ferrand M, Galy A, Boisgerault F. A dystrophic muscle broadens the contribution and activation of immune cells reacting to rAAV gene transfer. Gene Ther 2014;21:828-839.
110. Cordier L, Gao GP, Hack AA, et al. Musclespecific promoters may be necessary for adenoassociated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther 2001;12:205-215.
111. He Y, Weinberg MS, Hirsch M, et al. Kinetics of adeno-Associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical. Hum Gene Ther 2013;24:545-553.
112. Li C, He Y, Nicolson S, et al. Adeno-Associated virus capsid antigen presentation is dependent on endosomal escape. J Clin Invest 2013;123: 1390-1401.
113. Zhong L, Zhao W, Wu J, et al. A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral secondstrand DNA synthesis. Mol Ther 2007;15:1323-1330.
114. Zhong L, Li B, Jayandharan G, et al. Tyrosinephosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology 2008;381:194-202.
115. Zhong L, Li B, Mah CS, et al. Next generation of adeno-Associated virus 2 vectors: Point mutations in tyrosines lead to high-Efficiency transduction at lower doses. Proc Natl Acad Sci USA 2008;105:7827-7832.
116. Martino AT, Basner-Tschakarjan E, Markusic DM, et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 2013;121: 2224-2233.
117. Qiao C, Zhang W, Yuan Z, et al. AAV6 capsid tyrosine to phenylalanine mutations improve gene transfer to skeletal muscle. Hum Gene Ther 2010;21:1343-1348.
118. Shin JH, Pan X, Hakim CH, et al. Microdystrophin ameliorates muscular dystrophy in the canine model of Duchenne muscular dystrophy. Mol Ther 2013;21:750-757.
119. Sen D, Gadkari RA, Sudha G, et al. Targeted modifications in adeno-Associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo. Hum Gene Ther Methods 2013;24:104-116.
120. Sen D, Balakrishnan B, Gabriel N, et al. Improved adeno-Associated virus (AAV) serotype 1 and 5 vectors for gene therapy. Sci Rep 2013;3:1832.
121. Aslanidi GV, Rivers AE, Ortiz L, et al. High-Efficiency transduction of human monocyte-Derived dendritic cells by capsid-modified recombinant AAV2 vectors. Vaccine 2012;30:3908-3917.
122. Aslanidi GV, Rivers AE, Ortiz L, et al. Optimization of the capsid of recombinant adenoassociated virus 2 (AAV2) vectors: The final threshold?. PLoS One 2013;8:e59142.
123. Mays LE, Wang L, Lin J, et al. AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion and minimal MHCI upregulation on target cells. Mol Ther 2014;22:28-41.
124. Zhang Y, Chirmule N, Gao G, et al. CD40 liganddependent activation of cytotoxic T lymphocytes by adeno-Associated virus vectors in vivo: Role of immature dendritic cells. J Virol 2000;74: 8003-8010.
125. Jooss K, Yang Y, Fisher KJ, et al. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998;72:4212-4223.
126. Tsai RK, Discher DE. Inhibition of self engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol 2008;180:989-1003.
127. Rodriguez PL, Harada T, Christian DA, et al. Minimal self peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 2013;339:971-975.
128. Kotterman MA, Schaffer DV. Engineering adenoassociated viruses for clinical gene therapy. Nat Rev Genet 2014;15:445-451.
129. Cadwell RC, Joyce GF. Randomization of genes by PCR mutagenesis. PCR Methods Appl 1992;2: 28-33.
130. Cadwell RC, Joyce GF. Mutagenic PCR. PCR Methods Appl 1994;3:S136-S140.
131. Cadwell RC, Joyce GF. Mutagenic PCR. CSH Protoc 2006;prot4143.
132. Cirino PC, Mayer KM, Umeno D. Generating mutant libraries using error-prone PCR. Methods Mol Biol 2003;231:3-9.
133. Pritchard L, Corne D, Kell D, et al. A general model of error-prone PCR. J Theor Biol 2005;234: 497-509.
134. Perabo L, Endell J, King S, et al. Combinatorial engineering of a gene therapy vector: Directed evolution of adeno-Associated virus. J Gene Med 2006;8:155-162.
135. Rabinowitz JE, Bowles DE, Faust SM, et al. Cross-Dressing the virion: The transcapsidation of adeno-Associated virus serotypes functionally defines subgroups. J Virol 2004;78:4421-4432.
136. Aguinaldo AM, Arnold FH. Staggered extension process (StEP) in vitro recombination. Methods Mol Biol 2003;231:105-110.
137. Zhao H, Giver L, Shao Z, et al. Molecular evolution by staggered extension process (StEP) in vitro recombination. Nat Biotechnol 1998;16:258-261.
138. Zhao H, Zha W. In vitro sexual evolution through the PCR-based staggered extension process (StEP). Nat Protoc 2006;1:1865-1871.
139. Luo F, Du X, Weng T, et al. Efficient multi-sitedirected mutagenesis directly from genomic template. J Biosci 2012;37:965-969.
140. Luo WG, Liu HZ, et al. Simultaneous splicing of multiple DNA fragments in one PCR reaction. Biol Proced Online 2013;15:9.
141. Stemmer WP. Rapid evolution of a protein in vitro by DNA shuffling. Nature 1994;370:389-391.
142. Stemmer WP. DNA shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution. Proc Natl Acad Sci USA 1994;91:10747-10751.
143. Kienle E, Senis E, Borner K, et al. Engineering and evolution of synthetic adeno-Associated virus (AAV) gene therapy vectors via DNA family shuffling. J Vis Exp 2012;62:e3819.
144. Koerber JT, Jang JH, Schaffer DV. DNA shuffling of adeno-Associated virus yields functionally diverse viral progeny. Mol Ther 2008;16:1703-1709.
145. Nonnenmacher M, van Bakel H, Hajjar RJ, et al. High capsid-genome correlation facilitates creation of AAV libraries for directed evolution. Mol Ther 2015;23:675-682.
146. Yang L, Jiang J, Drouin LM, et al. A myocardium tropic adeno-Associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci USA 2009;106:3946-3951.
147. Pulicherla N, Shen S, Yadav S, et al. Engineering liver-Detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther 2011;19:1070-1078.
148. Li W, Asokan A, Wu Z, et al. Engineering and selection of shuffled AAV genomes: A new strategy for producing targeted biological nanoparticles. Mol Ther 2008;16:1252-1260.
149. Arnett AL, Konieczny P, Ramos JN, et al. Adenoassociated viral (AAV) vectors do not efficiently target muscle satellite cells. Mol Ther Methods Clin Dev 2014;1. pii: 14038.
150. Perrin S. Preclinical research: Make mouse studies work. Nature 2014;507:423-425.
151. Collins FS, Tabak LA. Policy: NIH plans to enhance reproducibility. Nature 2014;505:612-613.
152. Perel P, Roberts I, Sena E, et al. Comparison of treatment effects between animal experiments and clinical trials: Systematic review. Brit Med J 2007;334:197.
153. Lisowski L, Dane AP, Chu K, et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 2014;506:382-386.
154. Zhang Y, King OD, Rahimov F, et al. Human skeletal muscle xenograft as a new preclinical model for muscle disorders. Hum Mol Genet 2014;23:3180-3188.
155. Maheshri N, Koerber JT, Kaspar BK, et al. Directed evolution of adeno-Associated virus yields enhanced gene delivery vectors. Nat Biotechnol 2006;24:198-204.
156. Grimm D, Lee JS, Wang L, et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adenoassociated viruses. J Virol 2008;82:5887-5911.
157. Koenig M, Hoffman EP, Bertelson CJ, et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987;50:509-517.
158. Lostal W, Kodippili K, Yue Y, et al. Full-length dystrophin reconstitution with adeno-Associated viral vectors. Hum Gene Ther 2014;25:552-562.
159. Zhang Y, Yue Y, Li L, et al. Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy. Hum Mol Genet 2013;22:3720-3729.
160. Allocca M, Doria M, Petrillo M, et al. Serotypedependent packaging of large genes in adenoassociated viral vectors results in effective gene delivery in mice. J Clin Invest 2008;118:1955-1964.
161. Lai Y, Yue Y, Duan D. Evidence for the failure of adeno-Associated virus serotype 5 to package a viral genome > or = 8.2 kb. Mol Ther 2010;18: 75-79.
162. Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. Mol Ther 2010;18:80-86.
163. Dong B, Nakai H, Xiao W. Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther 2010;18:87-92.
164. Carrasco C, Castellanos M, de Pablo PJ, Mateu MG. Manipulation of the mechanical properties of a virus by protein engineering. Proc Natl Acad Sci USA 2008;105:4150-4155.
165. Yan Z, Keiser NW, Song Y, et al. A novel chimeric adenoassociated virus 2/human bocavirus 1 parvovirus vector efficiently transduces human airway epithelia. Mol Ther 2013;21: 2181-2194.
166. Qing K, Mah C, Hansen J, et al. Human fibroblast growth factor receptor 1 is a coreceptor for infection by adeno-Associated virus 2. Nat Med. 1999;5:71-77.
167. Ling C, Lu Y, Kalsi JK, et al. Human hepatocyte growth factor receptor is a cellular co-receptor for adeno-Associated virus serotype 3. Hum Gene Ther 2010;21:1741-1747.
168. Lerch TF, Chapman MS. Identification of the heparin binding site on adeno-Associated virus serotype 3B. Virology 2012;423:6-13.
169. Di Pasquale G, Davidson BL, Stein CS, et al. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 2003;9:1306-1312.
170. Akache B, Grimm D, Pandey K, et al. The 37/67-kilodalton laminin receptor is a receptor for adeno-Associated virus serotypes 8, 2, 3, and 9. J Virol 2006;80:9831-9836.
171. Seow Y, Yin H, Wood MJ. Identification of a novel muscle targeting peptide in mdx mice. Peptides 2010;31:1873-1877.
172. Halder S, Van Vliet K, Smith JK, et al. Structure of neurotropic adeno-Associated virus AAVrh.8. Journal of structural biology 2015;192:21-36.